Team tern for the win

Jane McCracken has spent her career working with high growth technology businesses based in the USA. UK and Europe as an entrepreneur, investor, board member and advisor. Her experience covers a variety of areas including software, e-commerce, digital health and clinical research.  She recently served as an Entrepreneur-in-Residence at the Advanced Technology Development Center, the state incubator based at Georgia Institute of Technology.  She is the Chief Growth Officer for Corps Team, a US-based search and staffing firm supporting startups to the Fortune 500.  Jane also serves on the board of London Stock Exchange Main Market listed Edinburgh Worldwide Investment Trust plc, which invests globally in high growth companies; and Radyus Research, a US-based privately held company that advises on drug discovery, lead candidate selection, and enabling studies.

Bruce led Tern’s initial investment of Cryptosoft and InVMA and led the acquisition of Amiho and Wyld to create Wyld Networks.

Bruce works with our investee companies and partners to develop interest and investment into the Tern portfolio.

Bruce began his IT career with IBM and has over 30 years board level experience, specialising in delivering high growth, high-profit results through product positioning and go-to-market strategies.

Bruce has extensive International Sales Management experience including Europe,  the US and Asia Pacific regions. He has been involved in a number of successful exits including Interactive/Dataworks, London Bridge and Codestream

Ian has a degree in Computer Science from Heriot-Watt University (1973) and holds Honorary Doctorates from Robert Gordons, Abertay, Heriot-Watt and Edinburgh Universities.

His TED talk has been viewed over 600,000 times.

Iain Ross has over 40 years’ experience in the international life sciences and technology sectors and has held significant roles in multi-national pharmaceutical and biotech companies.  He has completed multiple financing transactions and has over 30 years’ experience in cross-border management as a chairman or CEO.  He has led or participated in eight IPOs and has direct experience of M&A transactions in Europe, the USA and the Pacific Rim.  Currently he is Chairman of NASDAQ listed Silence Therapeutics plc, Executive Chairman of ReNeuron Group plc and internationally holds other non-executive director roles.